ULTRA Fel-O-Vax FVRCPThis page contains information on ULTRA Fel-O-Vax FVRCP for veterinary use.
The information provided typically includes the following:
- ULTRA Fel-O-Vax FVRCP Indications
- Warnings and cautions for ULTRA Fel-O-Vax FVRCP
- Direction and dosage information for ULTRA Fel-O-Vax FVRCP
ULTRA Fel-O-Vax FVRCPThis treatment applies to the following species:
Feline Rhinotracheitis-Calici-Panleukopenia Vaccine
For use in animals only
This product has been shown to be effective for the vaccination of healthy cats 8 weeks of age or older, against feline rhinotracheitis, calici and panleukopenia viruses. The duration of immunity for this product has not been established. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.
The vaccine contains one additional feline calicivirus strain isolated from one hemorrhagic calicivirus outbreak that occurred in 1998 and has been demonstrated effective against calicivirus-induced hemorrhagic disease in controlled vaccination challenge experiments.
Dose: Inject one 0.5 mL dose subcutaneously using aseptic technique. Healthy cats should receive two doses, 3 to 4 weeks apart, except that if the animal is less than 16 weeks of age, the final dose should be given no earlier than 16 weeks of age. The presence of maternal antibody is known to interfere with the development of active immunity in cats and additional boosters will be required in most young animals.
Historically, annual revaccination with a single dose has been recommended for this product.The need for this booster has not been established. For advice on revaccination frequency and annual booster vaccinations, consultation with a veterinarian is recommended.
ULTRA Fel-O-Vax FVRCP Caution
Store in the dark at 2° to 8°C (35° to 46°F). AVOID FREEZING. SHAKE WELL. A small percentage of patients may experience transient lethargy, pyrexia and anorexia, and some cats may show transient discomfort (such as stinging, itching or pain) at the injection site. In exceptional circumstances, hypersensitivity or anaphylaxis may occur, requiring appropriate symptomatic treatment.
Do not mix with other products, except as specified on the label. This product has not been tested in pregnant animals. In case of human exposure, contact a physician.
Thimerosal, neomycin, polymyxin B and amphotericin B added as preservatives.
ULTRA Fel-O-Vax FVRCP Caution
In the absence of a veterinarian-client-patient relationship, Federal law prohibits the relabeling, repackaging, resale, or redistribution of the individual contents of this package.
ULTRA, Fel-O-Vax, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
© 2017 Elanco US Inc. all rights reserved.
Elanco US Inc., Fort Dodge, IA 50501
25 Doses/25 x 0.5 mL Vials of Vaccine
Distributed by ELANCO US, INC.
2500 INNOVATION WAY, GREENFIELD, IN, 46140
|Every effort has been made to ensure the accuracy of the ULTRA Fel-O-Vax FVRCP information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2021 Animalytix LLC. Updated: 2020-12-31